Zhongguancun Biomedical Park Invites You to Participate in CSGCT 2025 – Showcasing Integrated Innovation Platforms for Cell and Gene Therapy

With over 1,000 square meters of specialized laboratories—including a molecular protein laboratory, cell culture room, and cryopreservation facility—the center is equipped with more than 100 sets of professional instruments for molecular biology, cell biology, biochemistry, and microbiology. It supports biotechnology innovation and entrepreneurship projects through multi-modal services, comprehensively addressing the needs of early-stage R&D and startup launch phases.

Spanning over 1,100 square meters, the facility features three production lines constructed in strict compliance with the 2010 GMP standards: a microbial fermentation workshop, a mammalian cell culture workshop, and an aseptic preparation workshop (including freeze-dried powder injection and liquid injection production lines). This flexible manufacturing suite fully enables precise simulation of production processes, integrating centralized pilot-scale process development and clinical sample production to meet the demands for preclinical and clinical trial sample preparation across diverse product types.

Covering an area of 325 m², the specialized facility is equipped with 13 sets of core equipment and features two independent cell culture rooms and virus handling rooms, as well as dedicated cell storage and cell quality control laboratories. It provides R&D and production environments and professional technical services compliant with Chinese standards for products such as plasmids, cell therapies, gene therapies, and viral vectors, thereby promoting the standardization, scalability, safety, and shared utilization of cell production processes.

A Class C sterile workshop established in accordance with the Good Manufacturing Practice for Medical Devices, equipped with dedicated positive-pressure rooms, microbial limit testing rooms, and sterility testing rooms, provides comprehensive hardware support covering the entire process from production to testing. We offer integrated services spanning concept verification, product manufacturing, and quality testing, covering the full pilot-scale cycle for Class II and III medical devices and in vitro diagnostic reagents.

A third-party quality supervision agency accredited by CNAS (Registration No.: L21488) provides compliance testing in accordance with the Chinese Pharmacopoeia, national standards, and European and American standards. It offers rapid-response testing for samples from both within and outside the industrial park (including samples from laboratories and pilot-scale workshops). Core services include physicochemical analysis, instrumental analysis, biological testing, and personnel training.

We can provide you with——

• Angel investment in early-stage projects; comprehensive financial services focused on financing for startups in the early and growth stages

• Professional Technical Services and Incubation Services for Enterprises in the Biopharmaceutical Sector

• Instrumentation, equipment, facilities, and other specialized conditions covering R&D, pilot-scale (GMP), and trial production

• The Comprehensive Physical Environment Required for Launching a Startup Project

At Zhongguancun Biomedical Park, you can enjoy—

• Multi-level coverage by government departments at all levels, including the Ministry of Science and Technology, Beijing Municipal Government, Beijing Municipal Science & Technology Commission • Zhongguancun Administrative Committee, and Zhongguancun Science City, regarding policies on talent, R&D, and industry.

• Communicate with similar startups and successful entrepreneurs anytime, anywhere

• Leverage our years of accumulated resources to facilitate rapid and convenient communication and collaboration with various outsourcing and intermediary agencies.

• Leverage our resources to significantly lower the barrier to entry for startups and rapidly connect with potential investors.

Project Requirements——

• Innovation and Entrepreneurship Projects in the Biopharmaceutical Field

• New Startup Projects Backed by Core Technologies

• Startups Willing to Establish Residency in Beijing, Leveraging the City’s Advantages in Technological Innovation

Contact Number: 010-82898313

Contact: Cao Ronghui 13699247129

Address: No. 5, Kaituo Road, Shangdi, Haidian District, Beijing

Special Notice

The 2025 Second China Society for Gene and Cell Therapy (CSGCT) Congress has specially planned“2025 CSGCT Conference Project Pitch” Session, bringing together 1,000+ high-quality domestic and international investment institutions, industrial investors, and decision-makers from government industrial guidance funds; attracting multinational corporations (MNCs) as well as renowned domestic and international medical and pharmaceutical companies seeking business development (BD) collaborations with outstanding projects, products, and technologies; and accelerating the exchange and cooperation on the most distinctive new technologies, new products, and new ecosystems in China’s cell and gene therapy (CGT) sector.